“We expected DPP-4 (dipeptidyl peptidase-4) inhibitors’ antifibrotic effects shown in animal experiments to lead to clinical benefits. Unfortunately, they did not. In diabetes treatment, drugs that have proved various additional benefits, including cardiovasc…